Get the Stockscreener App
17.35
1.11%
+0.19
Guardant Health Inc stock is currently priced at $17.35, with a 24-hour trading volume of 692.62K.
It has seen a +1.11% increased in the last 24 hours and a -1.92% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $17.32 pivot point. If it approaches the $17.70 resistance level, significant changes may occur.
Previous Close:
$17.16
Open:
$16.98
24h Volume:
692.62K
Market Cap:
$2.11B
Revenue:
$563.95M
Net Income/Loss:
$-479.45M
P/E Ratio:
-4.2734
EPS:
-4.06
Net Cash Flow:
$-345.46M
1W Performance:
+7.97%
1M Performance:
-1.92%
6M Performance:
-32.15%
1Y Performance:
-17.14%
1D Range:
$16.77
$17.52
52W Range:
$15.81
$41.06
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
505 Penobscot Drive, Redwood City
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Key Takeaways From Guardant Health Analyst Ratings
Benzinga
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks Investment Research
Analyst Expectations For Guardant Health's Future
Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Benzinga
Insiders Buying Advance Auto Parts And 2 Other Stocks
Benzinga
Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test
Benzinga
Guardant Health Inc Stock (GH) Financials Data
Guardant Health Inc (GH) Revenue 2024
GH reported a revenue (TTM) of $563.95 million for the quarter ending December 31, 2023, a +25.45% rise year-over-year.
Guardant Health Inc (GH) Net Income 2024
GH net income (TTM) was -$479.45 million for the quarter ending December 31, 2023, a +26.76% increase year-over-year.
Guardant Health Inc (GH) Cash Flow 2024
GH recorded a free cash flow (TTM) of -$345.46 million for the quarter ending December 31, 2023, a +10.72% increase year-over-year.
Guardant Health Inc (GH) Earnings per Share 2024
GH earnings per share (TTM) was -$4.28 for the quarter ending December 31, 2023, a +33.12% growth year-over-year.
Guardant Health Inc Stock (GH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| POTTER MYRTLE S | Director |
Apr 15 '24 |
Option Exercise |
0.00 |
68 |
0 |
7,582 |
| Tariq Musa | Director |
Apr 15 '24 |
Option Exercise |
0.00 |
249 |
0 |
3,247 |
| Joyce Meghan V. | Director |
Apr 04 '24 |
Option Exercise |
0.00 |
67 |
0 |
4,588 |
| Saia John G. | Chief Legal Officer |
Apr 01 '24 |
Option Exercise |
0.00 |
974 |
0 |
22,305 |
| Kalia Kumud | Chief Information Officer |
Apr 01 '24 |
Option Exercise |
0.00 |
1,607 |
0 |
14,329 |
| Freeman Chris | Chief Commercial Officer |
Apr 01 '24 |
Option Exercise |
0.00 |
1,929 |
0 |
16,502 |
| EAGLE CRAIG | Chief Medical Officer |
Apr 01 '24 |
Option Exercise |
0.00 |
1,714 |
0 |
12,073 |
| Chudova Darya | Chief Technology Officer |
Apr 01 '24 |
Option Exercise |
0.00 |
1,340 |
0 |
36,831 |
| Krognes Steve E. | Director |
Mar 31 '24 |
Option Exercise |
0.00 |
154 |
0 |
3,239 |
| Talasaz AmirAli | Co-Chief Executive Officer |
Mar 31 '24 |
Option Exercise |
0.00 |
11,461 |
0 |
1,913,806 |
About Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
0.03%
Cap:
|
Volume (24h):